Is OPKO Health, Inc. (OPK) a Buy, Sell, or Hold?
NASDAQ : OPK
OPKO Health, Inc.
$1.22 USD
$0.05 (4.27%)
- Volume
- 2.55M
- Average Volume
- 2.87M
- Market Capitalization
- $921.21M
- P/E Ratio
- -4.43
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $1.61
- Year Low
- $0.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.61
Company Overview
NASDAQ
Phillip Frost
Biotechnology
Healthcare
OPK
2275
US
USD
Liquidity Metrics
0.33
3.61
3.17
2.30
0.00
Sales & Valuation
$606.88M
1.59
0.77
-5.29
-0.23
Profitability
-$0.3
-$225.68M
-36.64%
-39.40%
-16.78%
-11.47%
P/E Metrics
-4.43
0.02
0.02
Analyst Price Target & Rating
$3.00
$4.00
$1.60
2/5
13 Analysts
-59.33%
Financial Health Scores
-0.59
3/9
$386.98M
$1.86B
$652.19M
-$125.03M
Key Metrics (TTM)
$976.26M
1.68
-28.14
3.61
-16.78%
-10.90%
-23.00%
-18.91%
84 days
Company Executives
| Name | Title |
|---|---|
| Steven D. Rubin | Executive Vice President of Administration & Director |
| Gene Yau | Head of Business Development |
| Hans Berner | President of OPKO Health Iberoamerica |
| Adam E. Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Treasurer |
| Akhtar Ashfaq | Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal |
| Giovanni Abbadessa | Chief Medical Officer of ModeX |
| Charles W. Bishop | Chief Executive Officer of OPKO Renal |
| Gary J. Nabel | Chief Information Officer & Director |
| John R. Mascola | Chief Scientific Officer of ModeX |
| Phillip Frost | Chairman of the Board & CEO |
| Jane H. Hsiao | Vice Chairman of the Board & Chief Technical Officer |
| Elias Adam Zerhouni | President & Vice Chairman of the Board |
Poll Results
No votes yet today — be the first to share your view!
About OPKO Health, Inc. (NASDAQ:OPK) Stock
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrum ... ent system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
2026-07-23 13:26:09
OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
2026-07-23 12:30:00
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
2026-07-23 12:30:00
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026.
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
2026-06-15 08:00:00
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available here, was presented by Moran Golan, Ph.D., Director of Preclinical & Clinical Pharmacology at OPKO Biologics.
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
2026-05-28 12:36:30
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
2026-05-21 13:26:05
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
2026-05-12 08:00:00
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models.
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
2026-04-30 08:30:00
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is approved in Macau, and the companies expect regulatory approvals in China and related territories in 2027.
Frequently Asked Questions
-
What is the current OPKO Health, Inc. (OPK) stock price?
-
OPKO Health, Inc.(NASDAQ:OPK) stock price is $1.22 in the last trading session. During the trading session, OPK stock reached the peak price of $1.61 while $0.98 was the lowest point it dropped to. The percentage change in OPK stock occurred in the recent session was 4.27% while the dollar amount for the price change in OPK stock was $0.05.
-
OPK's industry and sector of operation?
-
The NASDAQ listed OPK is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of OPK?
-
Steven D. Rubin | Executive Vice President of Administration & Director
Gene Yau | Head of Business Development
Hans Berner | President of OPKO Health Iberoamerica
Adam E. Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Treasurer
Akhtar Ashfaq | Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal -
How many employees does OPK have?
-
Number of OPK employees currently stands at 2275. OPK operates from 4400 Biscayne Boulevard, Miami, FL 33137, US.
-
Link for OPK official website?
-
Official Website of OPK is: https://www.opko.com
-
How do I contact OPK?
-
OPK could be contacted at phone #305 575 4100 and can also be accessed through its website. OPK operates from 4400 Biscayne Boulevard, Miami, FL 33137, US.
-
How many shares of OPK are traded daily?
-
The average number of OPK shares traded daily for last 3 months was 2.87M.
-
What is the market cap of OPK currently?
-
The market value of OPK currently stands at $921.21M with its latest stock price at $1.22